Alphatec (ATEC) to Release Earnings on Wednesday

Alphatec (NASDAQ:ATEC) is expected to post its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Alphatec to post earnings of ($0.18) per share and revenue of $172.74 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

Alphatec Stock Up 2.0 %

ATEC opened at $10.96 on Wednesday. Alphatec has a fifty-two week low of $4.88 and a fifty-two week high of $15.69. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32. The company has a market capitalization of $1.55 billion, a P/E ratio of -8.56 and a beta of 1.43. The stock has a fifty day moving average of $10.39 and a 200-day moving average of $8.14.

Insider Buying and Selling

In other Alphatec news, EVP David Sponsel sold 58,283 shares of Alphatec stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $10.71, for a total value of $624,210.93. Following the transaction, the executive vice president now owns 502,311 shares in the company, valued at $5,379,750.81. The trade was a 10.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Scott Lish sold 27,453 shares of Alphatec stock in a transaction dated Thursday, February 6th. The shares were sold at an average price of $11.49, for a total value of $315,434.97. Following the completion of the transaction, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. This represents a 3.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 222,376 shares of company stock worth $2,557,148. Company insiders own 22.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Barclays lifted their target price on Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Wednesday, January 22nd. HC Wainwright reissued a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Finally, Needham & Company LLC lifted their target price on Alphatec from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, Alphatec has a consensus rating of “Moderate Buy” and a consensus price target of $17.56.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.